LENZ Therapeutics, Inc. Stock OTC Markets
Stocks
GRPH
US52635N1037
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 147M 126M 118M 108M 202M 14.07B 205M 1.39B 543M 7.07B 552M 540M 23.38B | P/E 2026 * |
-1.1x | P/E 2027 * | -1.52x |
|---|---|---|---|---|---|
| Enterprise Value | 147M 126M 118M 108M 202M 14.07B 205M 1.39B 543M 7.07B 552M 540M 23.38B | EV / Sales 2026 * |
8.66x | EV / Sales 2027 * | 3.42x |
| Free-Float |
97.35% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: LENZ Therapeutics, Inc.
| 1 day | -2.75% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.75% | -4.79% | - | - | 147M | |
| -3.00% | +2.27% | +77.60% | +109.33% | 72.12B | |
| +1.90% | +23.53% | +56.60% | +97.76% | 65.85B | |
| +5.12% | +25.22% | +5.24% | -0.82% | 29.28B | |
| +0.55% | +1.64% | -5.15% | +471.68% | 27.47B | |
| +2.74% | +12.98% | +62.84% | +28.14% | 26.7B | |
| +0.47% | +6.12% | +36.66% | -13.79% | 20.06B | |
| +1.82% | -6.67% | +247.46% | +393.10% | 18.22B | |
| +0.94% | +3.36% | +18.55% | +532.94% | 16.4B | |
| +0.73% | +5.54% | +39.71% | +153.07% | 13.4B | |
| Average | +0.85% | +8.36% | +59.94% | +196.82% | 32.17B | |
| Weighted average by Cap. | +0.74% | +9.48% | +59.05% | +157.80% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 16.99M 14.55M 13.62M 12.47M 23.39M 1.63B 23.7M 161M 62.74M 817M 63.79M 62.41M 2.7B | 42.99M 36.83M 34.46M 31.54M 59.19M 4.11B 59.98M 407M 159M 2.07B 161M 158M 6.83B |
| Net income | -137M -117M -110M -100M -188M -13.08B -191M -1.29B -505M -6.57B -513M -502M -21.72B | -104M -88.84M -83.13M -76.09M -143M -9.92B -145M -982M -383M -4.99B -389M -381M -16.49B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
